Myricetin

Myricetin

SCHEMBL2278240

O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12.O=c1c(O)c(-c2ccccc2)oc2ccccc12

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 14/20 0.77
KMT2A Q03164 14/20 0.77
CYP3A4 P08684 11/20 0.77
MAPT P10636 8/20 0.77
CYP2C9 P11712 7/20 0.77
ABCB1 P08183 7/20 0.77
CYP2D6 P10635 6/20 0.77
CYP2C19 P33261 6/20 0.77
CYP1B1 Q16678 5/20 0.77
CYP1A2 P05177 5/20 0.77
FTO Q9C0B1 5/20 0.77
CYP1A1 P04798 4/20 0.77
BCHE P06276 4/20 0.77
ACHE P22303 4/20 0.77
XDH P47989 4/20 0.77
CA12 O43570 4/20 0.77
CYP19A1 P11511 3/20 0.77
MAOA P21397 3/20 0.77
PPARG P37231 3/20 0.77
CA7 P43166 3/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Galangin SCHEMBL7926038 0.95 MEN1 (0.85) MEN1KMT2ACYP3A4MAPTCYP2C9
Kaempferol SCHEMBL31164054 0.92 MEN1 (0.79) MEN1KMT2ACYP3A4MAPTCYP2C9
Kaempferol SCHEMBL1485787 0.92 MEN1 (0.79) MEN1KMT2ACYP3A4MAPTCYP2C9
Quercetin SCHEMBL111510 0.91 MEN1 (0.76) MEN1KMT2ACYP3A4MAPTCYP2C9
Datiscetin SCHEMBL15675904 0.90 MEN1 (0.75) MEN1KMT2ACYP3A4MAPTCYP2C9
Morin SCHEMBL2118429 0.90 MEN1 (0.75) MEN1KMT2ACYP3A4MAPTCYP2C9
Galangin SCHEMBL117225 0.88 MEN1 (1.00) MEN1KMT2ACYP3A4MAPTCYP2C9
Galangin SCHEMBL29393121 0.88 MEN1 (1.00) MEN1KMT2ACYP3A4MAPTCYP2C9
Kaempferide SCHEMBL19097707 0.86 ABCB1 (0.79) MEN1KMT2ACYP3A4MAPTCYP2C9
Myricetin SCHEMBL19302 0.85 MEN1 (1.00) MEN1KMT2ACYP3A4MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115636859-A Method for simultaneously separating and purifying two galloylated myricitrin from waxberry leaves and application 浙江大学 2023-01-24 CN claimed
CN-116390645-A Grape rich in phenol 以色列农业和农村发展部农业研究组织(范卡尼中心) 2023-07-04 CN disclosed
CN-110261499-B Method for detecting chemical components in polygonum aviculare based on UPLC-Q-TOF/MS 江阴天江药业有限公司 2022-02-11 CN disclosed
US-20210333257-A1 METHODS AND COMPOSITIONS INVOLVING FLAVONOLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-10-28 US disclosed
US-20210317497-A1 MONBRETIN A (MBA) SYNTHESIS USING A HETEROLOGOUS NUCLEIC ACID(S) ENCODING A MBA PATHWAY ENZYME THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2021-10-14 US disclosed
WO-2020041310-A1 METHODS AND COMPOSITIONS INVOLVING FLAVONOLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-02-27 WO disclosed
WO-2019241895-A1 MONBRETIN A (MBA) SYNTHESIS USING A HETEROLOGOUS NUCLEIC ACID(S) ENCODING A MBA PATHWAY ENZYME THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2019-12-26 WO disclosed
CN-110261499-A A method of based on chemical component in UPLC-Q-TOF/MS Jian Ce pivot storage 江阴天江药业有限公司 2019-09-20 CN disclosed
CN-104507454-A Hair colouring compositions comprising gossypetin UNILEVER NV 2015-04-08 CN disclosed
EP-2209794-B1 ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF UNIV BRITISH COLUMBIA (CA) 2014-12-10 EP disclosed
CN-103221056-A Electronically Modified Reaction Intermediates MARKOU DEMETRIOS 2013-07-24 CN disclosed
US-8431541-B2 Alpha-amylase inhibitors: the montbretins and uses thereof THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-04-30 US disclosed
US-20110189107-A1 ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-08-04 US disclosed
EP-2209794-A1 ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2010-07-28 EP disclosed
US-20100075385-A1 O-Methyltransferases of Tetrahydrobenzylisoquinoline Alkaloid Biosynthesis in Papaver Somniferum DONALD DANFORTH PLANT SCIENCE CENTER (US) 2010-03-25 US disclosed
WO-2009049428-A1 ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2009-04-23 WO disclosed
US-7514251-B2 O-methyltransferases of tetrahydrobenzylisoquinoline alkaloid biosynthesis in Papaver somniferum DONALD DANFORTH PLANT SCIENCE CENTER (US) 2009-04-07 US disclosed
US-20050106588-A1 O-methyltransferases of tetrahydrobenzylisoquinoline alkaloid biosynthesis in Papaver somniferum DONALD DANFORTH PLANT SCIENCE CENTER 2005-05-19 US disclosed
WO-2005021763-A2 O-METHYLTRANSFERASES OF TETRAHYDROBENZYLISOQUINOLINE ALKALOID BIOSYNTHESIS IN PAPAVER SOMNIFERUM JOHNSON & JOHNSON RESEARCH PTY LTD (AU) 2005-03-10 WO disclosed
EP-1512748-A1 O-methyltransferases of tetrahydrobenzylisoquinoline alkaloid biosynthesis in papaver somniferum Johnson & Johnson Research Pty Limited (AU) 2005-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110189107-A1 ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF AMY1A, AMY2A, GBA3 MEN1 2138/4885KMT2A 2548/4885CYP3A4 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.